SCHEMBL3166015

SCHEMBL3166015

CC(NC(=O)c1ccc(S(=O)(=O)Nc2nccs2)cc1)c1ccccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 1/20 0.57
SCN8A Q9UQD0 7/20 0.55
SCN1A P35498 5/20 0.55
SCN5A Q14524 5/20 0.55
SCN1B Q07699 3/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
RXFP1 Q9HBX9 1/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
MCL1 Q07820 1/20 0.52
CA1 P00915 1/20 0.52
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163280 0.89 SCN3A (0.58) SCN3ASCN8ASCN1ASCN5ALMNA
SCHEMBL3169340 0.86 SCN3A (0.65) SCN3ASCN8ASCN1ASCN5ASCN1B
SCHEMBL3173762 0.86 SCN3A (0.65) SCN3ASCN8ASCN1ASCN5ASCN1B
SCHEMBL3154344 0.86 SCN3A (0.57) SCN3ASCN8ASCN1ASCN5ASCN1B
SCHEMBL3171500 0.81 PTPN1 (0.59) SCN3ALMNASMN1; SMN2MEN1KMT2A
SCHEMBL3163978 0.81 KMT2A (0.70) SCN3ASCN8ASCN1ASCN5ASCN1B
SCHEMBL3167250 0.81 KMT2A (0.70) SCN3ASCN8ASCN1ASCN5ASCN1B
SCHEMBL3169854 0.79 SCN3A (0.67) SCN3AMEN1KMT2ARXFP1ALDH1A1
SCHEMBL3154212 0.78 SCN3A (0.74) SCN3ALMNASMN1; SMN2MEN1KMT2A
SCHEMBL3163459 0.78 SCN3A (0.59) SCN3ALMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN8A 75/4885SCN1A 6/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885SCN8A 75/4885SCN1A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.